Young-Ho Lee
Chief Executive Officer bei Immunique Co. Ltd.
Profil
Young-Ho Lee is currently the Chief Executive Officer at Immunique Co. Ltd.
and a Professor at Hanyang University.
In 2022-2023, he served as an Independent Director at NanoenTek, Inc. He holds a doctorate degree from Hanyang University.
Aktive Positionen von Young-Ho Lee
| Unternehmen | Position | Beginn |
|---|---|---|
| Hanyang University | Corporate Officer/Principal | - |
Immunique Co. Ltd.
 Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Young-Ho Lee
| Unternehmen | Position | Ende |
|---|---|---|
| NANOENTEK, INC. | Director/Board Member | 08.09.2023 |
Ausbildung von Young-Ho Lee
| Hanyang University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NANOENTEK, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Immunique Co. Ltd.
Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Commercial Services |
